Design Therapeutics (NASDAQ:DSGN – Get Free Report)‘s stock had its “market perform” rating reissued by research analysts at SVB Leerink in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock. SVB Leerink’s price objective would indicate a potential upside of 82.93% from […]
Design Therapeutics (NASDAQ:DSGN – Get Free Report) and Alzamend Neuro (NASDAQ:ALZN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Risk & Volatility Design Therapeutics has a […]
The Goldman Sachs Group upgraded shares of Design Therapeutics (NASDAQ:DSGN – Get Rating) from a sell rating to a neutral rating in a report issued on Thursday morning, The Fly reports. The firm currently has $6.00 target price on the stock. Separately, Royal Bank of Canada reissued an outperform rating and issued a $24.00 price […]
The Goldman Sachs Group upgraded shares of Design Therapeutics (NASDAQ:DSGN – Get Rating) from a sell rating to a neutral rating in a research note issued to investors on Thursday, The Fly reports. The Goldman Sachs Group currently has $6.00 target price on the stock. Separately, Royal Bank of Canada reaffirmed an outperform rating and […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Rating)’s stock price rose 9.5% during trading on Monday . The company traded as high as $7.15 and last traded at $7.06. Approximately 254,246 shares changed hands during trading, a decline of 41% from the average daily volume of 433,583 shares. The stock had previously closed at $6.45. Analysts […]